denosumab

FDA Drug Profile — Prolia, XGEVA, WYOST, JUBBONTI, OSPOMYV

denosumab is listed in the FDA National Drug Code directory with 11 NDC codes, marketed under brand names including Prolia, XGEVA, WYOST. Available dosage forms: liquid, injection, solution, injection.

Drug details

Generic Name
denosumab
Brand Names
Prolia, XGEVA, WYOST, JUBBONTI, OSPOMYV
Application Number
BLA125320
Sponsor
Novartis Pharmaceuticals Corporation
NDC Codes
11
Dosage Forms
LIQUID, INJECTION, SOLUTION, INJECTION
Routes
SUBCUTANEOUS
Active Ingredients
DENOSUMAB, DENOSUMAB-DSSB

Indications and Usage

1 INDICATIONS AND USAGE Bilprevda is a RANK ligand (RANKL) inhibitor indicated for: Prevention of skeletal-related events in patients with multiple myeloma and in patients with bone metastases from solid tumors. ( 1.1 ) Treatment of adults and skeletally mature adolescents with giant cell tumor of bone that is unresectable or where surgical resection is likely to result in severe morbidity. ( 1.2 , 14.3 ) Treatment of hypercalcemia of malignancy refractory to bisphosphonate therapy. ( 1.3 ) 1.1 Multiple Myeloma and Bone Metastasis from Solid Tumors Bilprevda is indicated for the prevention of skeletal-related events in patients with multiple myeloma and in patients with bone metastases from solid tumors. 1.2 Giant Cell Tumor of Bone Bilprevda is indicated for the treatment of adults and skeletally mature adolescents with giant cell tumor of bone that is unresectable or where surgical resection is likely to result in severe morbidity [see Clinical Trials ( 14.2 )] . 1.3 Hypercalcemia of Malignancy Bilprevda is indicated for the treatment of hypercalcemia of malignancy refractory to bisphosphonate therapy.

Sources: openFDA, FDA Data Dashboard, FDA.gov. Report a data issue: hello@regdatalab.com.